Can I read Ribociclib in Pediatric Solid Tumors on EtoBox?

Ribociclib in Pediatric Solid Tumors by Matt is a document available to read on EtoBox.

What is Ribociclib in Pediatric Solid Tumors about?

This phase I study evaluated the CDK4/6 inhibitor ribociclib in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. The study established a maximum tolerated dose of 470 mg/m2 and a recommended phase II dose of 350 mg/m2, with ribociclib showing an acceptable safety profile and preliminary signs of tumor stabilization. The findings support further investigation of ribociclib in combination with other therapies for these high-risk pediatric cancers.

Author

Matt

Language

EN